Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide vs Diet in Obesity
NCT05912621Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Nov 2023
- Primary completion
- Jun 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirzepatide in obesity and Overweight (2 arms), sponsored by Stanford University. Primary endpoints: Change in Adipocyte Size at Week 22, Change in Adipocyte Fat Storage Capacity at Week 22 and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05912621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912621.